Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 37

Sort by

Sort Order Select

Journal Articles

Disease presentation and immunophenotype characteristics in 257 patients with blastic plasmacytoid dendritic cell neoplasm: A pethema/PALG study

Beatriz Martín Herreros, Irene Navarro Vicente, Milena Sitkiewicz, Pilar Lloret Madrid, Łukasz Targoński, Amparo Sempere, Joaquín Sánchez-García, Josefina Serrano, Manuel Perez Encinas, Jorge Labrador, Delfim Duarte, Tomás Rivero Equiza, Olga Salamero, Rafael Colmenares, Maria Teresa Cedena Romero, Tamara Castaño, Anna Armatys, Alberto Giménez Conca, Cristina Gil, Teresa Olave, Lorenzo Algarra, María García-Fortes, Juan Miguel Bergua Burgues, Gabriela Rodriguez Macias, Manuel Barrios García, Eduardo Rodríguez-Arbolí, Teresa Caballero-Velazquez, Dunia De Miguel, Fernanda Trigo, Joana Brioso Infante, Emilia Ulenberg, Bruno Paiva, Virginia Pradillo Fernandez, Mar Tormo, Victor Noriega Concepción, Teresa Bernal Del Castillo, Rolando Omar Vallansot, Mercedes Colorado, Lisette Costilla-Barriga, Matxalen Olivares Salaverri, Isabel Simón-Pilo, Nerea Caminos, Ada Esteban-Figuerola, Małgorzata Sobczyk-Kruszelnicka, Renata Guzicka-Kazimierczak, Krzysztof Lewandowski, Andrzej Szczepaniak, Santiago Cranco, Manuela Clavijo, Irene Rey, Magdalena Karasek, Antonio Solana-Altabella, Leticia Rapan, Marta Sobas, Pau Montesinos

Blood (2025) 146 (Supplement 1): 218.

https://doi.org/10.1182/blood-2025-218

Published: 2025

Journal Articles

Temporal trends in overall survival among patients with high-risk MDS: Insights from the spanish MDS registry (RESMD)

Ana Alfonso-Pierola, Marina Diaz Beya, Teresa Bernal, David Valcarcel, Montserrat Arnan, María Luz Amigo, Joaquin Sanchez-Garcia, Raúl Azibeiro Melchor, Blanca Xicoy, Fernando Ramos, Mar Tormo, Joan Bargay, Maria Teresa Cedena Romero, Leonor Arenillas, Jose Francisco Falantes, Ariane Unamunzaga, Lourdes Hermosin Ramos, Maria Diez-Campelo

Blood (2025) 146 (Supplement 1): 3868.

https://doi.org/10.1182/blood-2025-3868

Published: 2025

Journal Articles

Impact of molecular profile and variant allele frequency in patients with Acute Myeloid Leukemia undergoing allogeneic transplantation in first remission: A study by the pethema group

Rafael Colmenares, Eva Barragán, Rebeca Rodriguez-Veiga, Laura Torres-Miñana, Joaquín Sánchez-García, Mar Tormo, Teresa Bernal Del Castillo, Pilar Martinez Sanchez, Eduardo Rodríguez-Arbolí, Cristina Gil, Elena Soria-Saldise, Josefina Serrano, Mercedes Colorado, María García-Fortes, Cristina Bilbao, José Luis López Lorenzo, Maria Jose Larrayoz, Esther Pérez-Santaolalla, Esperanza Lavilla-Rubira, Lorenzo Algarra, Maria Carmen García-Garay, Carmen Chillon, Melissa Torres-Ochando, Raimundo García-Boyero, Carmen Couto, Ágata Almela, Victor Noriega Concepción, Marta Callejas, Manuel Barrios García, Soledad Casado, Amaia Balerdi Malcorra, Ana Cabello, Jorge Labrador, María Carmen Mateos, María Luz Amigo, Manuel Pérez-Encinas, Maria Jose Garcia, Lisette Costilla-Barriga, Juan Miguel Bergua Burgues, Gonzalo Carreño, Joaquin Martinez-Lopez, Rosa Ayala Diaz, Pau Montesinos

Blood (2025) 146 (Supplement 1): 6998.

https://doi.org/10.1182/blood-2025-6998

Published: 2025

Journal Articles

Venetoclax in combination with hypomethylating agents in adult patients with newly diagnosed AML with CBFB::MYH11 or RUNX1::RUNX1T1 fusions: Real-world outcomes based on international registry data

Blood (2025) 146 (Supplement 1): 5230.

https://doi.org/10.1182/blood-2025-5230

Published: 2025

Journal Articles

Measurable residual disease (MRD) assessment as an early end point oftreatment efficacy in acute myeloid leukemia (AML): A pethema studyof 2,623 patients (Pts) treated with intensive therapy

Bruno Paiva, Leire Burgos, Carmen Gonzalez, Rebeca Rodriguez Veiga, Antonio Solana-Altabella, Pilar Lloret-Madrid, Evelyn Acuña-Cruz, Cristina Gil, Carmen Botella, Eduardo Rodríguez-Arbolí, Teresa Caballero, Teresa Bernal Del Castillo, Maria Teresa Cedena Romero, Pilar Herrera Puente, Claudia Sossa, Josefina Serrano, Joaquín Sánchez-García, José Luis López Lorenzo, María-Belén Vidriales, Mar Tormo, Monica Romero, Mercedes Colorado, Celina Benavente, Juan Miguel Bergua Burgues, Manuel Pérez-Encinas, Lorenzo Algarra, Carlos Rodríguez-Medina, Dolly Viviana Fiallo Suarez, Raimundo García-Boyero, Luis Felipe Casado Montero, Jorge Labrador, Manuel Barrios García, Beatriz De Rueda Ciller, Marcela Espinoza, Maria Jose Sayas Lloris, Diana Cuervo, María Luz Amigo, Jose-Mario Mariz, Karoll Giovanna Gomez Correcha, Carmen Couto, Esther Perez, Ágata Almela, Susana Vives, Esperanza Lavilla-Rubira, Olga Arce-Fernández, Maria Teresa Olave Rubio, Miguel Lopez, Maria Dolores Madrigal, Lara María Gómez García, Sofia Grille, Sebastián Hidalgo, Daniel García Belmonte, Maria Jose Garcia, Maria Del Carmen Martinez Chamorro, Olga Salamero, Amparo Sempere, Beatriz Martín Herreros, Armando Mena Duran, David Martinez-Cuadron, Pau Montesinos

Blood (2025) 146 (Supplement 1): 5293.

https://doi.org/10.1182/blood-2025-5293

Published: 2025

Journal Articles

A Multicenter, Prospective, Non-Randomized, Phase I-II Trial to Asses the Efficacy and Safety of the Combination or Oral Quizartinib and the FLAG-IDA Chemotherapy Regimen in First Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

Blood (2024) 144 (Supplement 1): 2874.

https://doi.org/10.1182/blood-2024-200280

Published: 2024

Journal Articles

Evolution of the Genetic and Biological Studies Performed at Diagnosis in Patients with Acute Myeloid Leukemia Included in the Pethema Epidemiological Registry (REALMOL Study)

Blood (2022) 140 (Supplement 1): 9100–9102.

https://doi.org/10.1182/blood-2022-163016

Published: 2022

Journal Articles

Machine Learning Model Defines Higher Risk of Venous Thromboembolism in Young Adults with Multiple Myeloma

Inés Martínez-Alfonzo, Diego Velasco, Pablo Mínguez Paniagua, Ignacio Mahillo-Fernández, Elham Askari, Rosa Vidal Laso, Cristina Fernández Maqueda, Alberto Velasco, Ana González-Teomiro, Maria Civeira-Marín, Elena Prieto-Pareja, Sara Martín-Herrero, José Manuel Calvo Villas, Isabel Krsnik, Joaquín Sánchez-Garcia, Miguel Angel Alvarez, María Pilar Llamas Sillero, Juana Serrano-López

Blood (2022) 140 (Supplement 1): 2811–2812.

https://doi.org/10.1182/blood-2022-167058

Published: 2022

Journal Articles

Long-Term Evolution of Somatic Mutations in Patients with Del(5q) MDS Early Treated with Lenalidomide in the Sintra-Rev Clinical Trial: Safe and Effecitive Approach?

Blood (2022) 140 (Supplement 1): 9740–9743.

https://doi.org/10.1182/blood-2022-168599

Published: 2022

Journal Articles

Evaluation of Lenalidomide (LEN) Vs Placebo in Non-Transfusion Dependent Low Risk Del(5q) MDS Patients. Final Results of Sintra-REV Phase III International Multicenter Clinical Trial

Blood (2022) 140 (Supplement 1): 1109–1111.

https://doi.org/10.1182/blood-2022-168718

Published: 2022

Journal Articles

Real-Life Comparative Analysis of Prognostic Risk Classification According to ELN 2010, 2017 and 2022 in AML Patients

Clara Aparicio Pérez, Ana Camila Gonzalez Teomiro, Maria Carmen Martinez Losada, Manuel Yébenes Ramírez, Carmen Martin Calvo, Esther Prados de La Torre, Joaquín Sánchez-Garcia, Josefina Serrano

Blood (2022) 140 (Supplement 1): 9136–9137.

https://doi.org/10.1182/blood-2022-163617

Published: 2022

Journal Articles

Pethema NGS-AML Project. Final Analysis and Clinical Validation of New Genomic Classifications

Blood (2022) 140 (Supplement 1): 3422–3424.

https://doi.org/10.1182/blood-2022-166639

Published: 2022

Journal Articles

Conventional PCR Versus Next Generation Sequencing for Diagnosis of FLT3 , IDH and NPM1 Mutations in Acute Myeloid Leukemia: Interim Analysis of the PCR-LMA Protocol of the Pethema Group

Blood (2022) 140 (Supplement 1): 3438–3440.

https://doi.org/10.1182/blood-2022-160136

Published: 2022

Journal Articles

Nationwide Laboratory Network for AML Cross-Validated NGS Studies: Results from a Real-Life Cohort of the Pethema Group

Blood (2021) 138 (Supplement 1): 1302.

https://doi.org/10.1182/blood-2021-152353

Published: 2021

Journal Articles

Clinical Impact of Copy Number Variation Revealed By Next Generation Sequencing in Acute Myeloid Leukemia

Kamila Janusz, Ruth Stuckey, Clara Aparicio Pérez, Cristina Bilbao, Inmaculada Fernández Camacho, Manuel Yébenes, Josefina Serrano, Jesús M Hernández Rivas, María Teresa Gómez-Casares, Joaquín Sánchez

Blood (2021) 138 (Supplement 1): 4463.

https://doi.org/10.1182/blood-2021-153302

Published: 2021

Journal Articles

Phase 3 Study of Lenalidomide (LEN) Vs Placebo in Non-Transfusion Dependent (TD) Low Risk Del(5q) MDS Patients - Interim Analysis of the European Sintra-REV Trial

Blood (2020) 136 (Supplement 1): 28–29.

https://doi.org/10.1182/blood-2020-140339

Published: 2020

Journal Articles

Impact of Measurable Residual Disease (MRD) By Multiparameter Flow Cytometry (MFC): A Real-World Study in 1,076 Patients with Acute Myeloid Leukemia (AML)

Bruno Paiva, PhD, María Belén Vidriales, Maria Desamparados Sampere Talens, Fabian Tarin, Enrique Colado, Celina Benavente, María Teresa Cedena, MD, Joaquin Sanchez, MD, Teresa Caballero-Velázquez, MD PhD, Lourdes Cordon, David Martínez-Cuadron, MD, Teresa Bernal del Castillo, MD PhD, Carmen Botella, Sofia Grille, MDPhD, Josefina Serrano, MD, Carlos Rodriguez, Jesús Lorenzo Algarra, Juan Manuel Alonso Dominguez, MD PhD MSc, Maria Luz Amigo, MD, Manuel BARRIOS García, MDPhD, Raimundo García-Boyero, MD, Mercedes Colorado, MD, Jaime Perez De Oteyza, MDPhD, Manuel Perez Encinas, MD, Lissette Del Pilar Costilla, MD, Maria Jose Sayas, Olga Pérez-López, Marcos González, Jose A. Perez-Simon, MD PhD, Joaquin Martinez-Lopez, MD PhD, Claudia Lucia Sossa, Alberto Orfao, MD PhD, Jesús F. San-Miguel, Miguel Sanz, MD PhD, Pau Montesinos, MD PhD

Blood (2020) 136 (Supplement 1): 13–15.

https://doi.org/10.1182/blood-2020-134349

Published: 2020

Journal Articles

Sequential Study By RNA-Seq Shows a Reduction in Inflammation and a Cell Cycle Activation in T-Lymphocytes from Myelodysplastic Syndrome with Del(5q) after Lenalidomide Treatment in Patients Included in the "Sintra-REV" Clinical Trial

Mónica Del Rey, Luis A Corchete, PhD, Teresa González, PhD, Félix López Cadenas, MD, Eva Lumbreras, Marta Martín Izquierdo, MSc, Sandra Santos-Mínguez, Sofía M Toribio, Blanca Xicoy, MD, Joaquín Sánchez-García, MD PhD, Teresa Bernal, MD PhD, Guillermo F Sanz, MD PhD, Benet Nomdedeu, MD, Pierre Fenaux, MD PhD, Jesús M Hernández Rivas, MD PhD, Maria Diez-Campelo, PhDMD

Blood (2020) 136 (Supplement 1): 26–27.

https://doi.org/10.1182/blood-2020-140703

Published: 2020

Journal Articles

Peripheral T-Cell Lymphomas in Spain: Profiling Clinical, Phenotypic and Genetic Characteristics in Spanish Population

Blood (2018) 132 (Supplement 1): 2938.

https://doi.org/10.1182/blood-2018-99-116562

Published: 2018

Journal Articles

Phase 3 Study of Lenalidomide (LEN) Vs Placebo in Non-Transfusion Dependent (TD) Low Risk Del(5q) MDS Patients with Del(5q) — Preliminary Blinded Analysis of the European Sintra-REV Trial

Blood (2018) 132 (Supplement 1): 468.

https://doi.org/10.1182/blood-2018-99-119430

Published: 2018

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Disease presentation and immunophenotype characteristics in 257 patients with blastic plasmacytoid dendritic cell neoplasm: A pethema/PALG study

Temporal trends in overall survival among patients with high-risk MDS: Insights from the spanish MDS registry (RESMD)

Impact of molecular profile and variant allele frequency in patients with Acute Myeloid Leukemia undergoing allogeneic transplantation in first remission: A study by the pethema group

Venetoclax in combination with hypomethylating agents in adult patients with newly diagnosed AML with CBFB::MYH11 or RUNX1::RUNX1T1 fusions: Real-world outcomes based on international registry data

Measurable residual disease (MRD) assessment as an early end point oftreatment efficacy in acute myeloid leukemia (AML): A pethema studyof 2,623 patients (Pts) treated with intensive therapy

A Multicenter, Prospective, Non-Randomized, Phase I-II Trial to Asses the Efficacy and Safety of the Combination or Oral Quizartinib and the FLAG-IDA Chemotherapy Regimen in First Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

Evolution of the Genetic and Biological Studies Performed at Diagnosis in Patients with Acute Myeloid Leukemia Included in the Pethema Epidemiological Registry (REALMOL Study)

Machine Learning Model Defines Higher Risk of Venous Thromboembolism in Young Adults with Multiple Myeloma

Long-Term Evolution of Somatic Mutations in Patients with Del(5q) MDS Early Treated with Lenalidomide in the Sintra-Rev Clinical Trial: Safe and Effecitive Approach?

Evaluation of Lenalidomide (LEN) Vs Placebo in Non-Transfusion Dependent Low Risk Del(5q) MDS Patients. Final Results of Sintra-REV Phase III International Multicenter Clinical Trial

Real-Life Comparative Analysis of Prognostic Risk Classification According to ELN 2010, 2017 and 2022 in AML Patients

Pethema NGS-AML Project. Final Analysis and Clinical Validation of New Genomic Classifications

Conventional PCR Versus Next Generation Sequencing for Diagnosis of FLT3 , IDH and NPM1 Mutations in Acute Myeloid Leukemia: Interim Analysis of the PCR-LMA Protocol of the Pethema Group

Nationwide Laboratory Network for AML Cross-Validated NGS Studies: Results from a Real-Life Cohort of the Pethema Group

Clinical Impact of Copy Number Variation Revealed By Next Generation Sequencing in Acute Myeloid Leukemia

Phase 3 Study of Lenalidomide (LEN) Vs Placebo in Non-Transfusion Dependent (TD) Low Risk Del(5q) MDS Patients - Interim Analysis of the European Sintra-REV Trial

Impact of Measurable Residual Disease (MRD) By Multiparameter Flow Cytometry (MFC): A Real-World Study in 1,076 Patients with Acute Myeloid Leukemia (AML)

Sequential Study By RNA-Seq Shows a Reduction in Inflammation and a Cell Cycle Activation in T-Lymphocytes from Myelodysplastic Syndrome with Del(5q) after Lenalidomide Treatment in Patients Included in the "Sintra-REV" Clinical Trial

Peripheral T-Cell Lymphomas in Spain: Profiling Clinical, Phenotypic and Genetic Characteristics in Spanish Population

Phase 3 Study of Lenalidomide (LEN) Vs Placebo in Non-Transfusion Dependent (TD) Low Risk Del(5q) MDS Patients with Del(5q) — Preliminary Blinded Analysis of the European Sintra-REV Trial

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only